These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17125641)

  • 41. [Gaucher disease: enzyme replacement treatment initiated at pediatric age; 20-year experience].
    Vitoria Miñana I; Dalmau Serra J
    An Pediatr (Barc); 2016 Jun; 84(6):343-6. PubMed ID: 26724255
    [No Abstract]   [Full Text] [Related]  

  • 42. [Gaucher disease type I diagnosed at 63 years old presenting with thrombocytopenia].
    Kawahara S; Kato A; Oshimi K; Ida H
    Rinsho Ketsueki; 2008 May; 49(5):335-9. PubMed ID: 18572811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?
    Brunel-Guitton C; Rivard GE; Galipeau J; Alos N; Miron MC; Therrien R; Mitchell G; Lapierre G; Lambert M
    Mol Genet Metab; 2009 Feb; 96(2):73-6. PubMed ID: 19083253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of Gaucher disease in a post-communist transitional health care system: Croatian experience.
    Mrsić M; Stavljenić-Rukavina A; Fumić K; Labar B; Bogdanić V; Potocki K; Kardum-Skelin I; Rovers D
    Croat Med J; 2003 Oct; 44(5):606-9. PubMed ID: 14515422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease.
    Czartoryska B; Tylki-Szymańska A; Lugowska A
    Clin Biochem; 2000 Mar; 33(2):147-9. PubMed ID: 10751594
    [No Abstract]   [Full Text] [Related]  

  • 46. Liposomes in Gaucher type I disease: use in enzyme therapy and the creation of an animal model.
    Gregoriadis G; Weereratne H; Blair H; Bull GM
    Prog Clin Biol Res; 1982; 95():681-701. PubMed ID: 6812092
    [No Abstract]   [Full Text] [Related]  

  • 47. Retinal Deposits in a Young Woman.
    Oliver R; Sallam AB; Uwaydat SH
    JAMA Ophthalmol; 2018 Jun; 136(6):708-709. PubMed ID: 29522126
    [No Abstract]   [Full Text] [Related]  

  • 48. Pulmonary arterial hypertension with plexogenic arteriopathy in enzyme-substituted Gaucher disease.
    den Bakker MA; Grünberg K; Boonstra A; van Hal PT; Hollak CE
    Histopathology; 2012 Aug; 61(2):324-6. PubMed ID: 22690977
    [No Abstract]   [Full Text] [Related]  

  • 49. Enzyme replacement therapy for Gaucher Disease: the only experience in Malaysia.
    Chan LL; Lin HP
    Med J Malaysia; 2002 Sep; 57(3):348-52. PubMed ID: 12440275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply.
    Zimran A; Altarescu G; Elstein D
    Blood Cells Mol Dis; 2011 Jan; 46(1):111-4. PubMed ID: 20542712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy.
    Santoro D; Rosenbloom BE; Cohen AH
    Am J Kidney Dis; 2002 Jul; 40(1):E4. PubMed ID: 12087590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report.
    Martinez-Redondo C; Ortuño FJ; Lozano ML; Jerez A; del Mar Osma M; Giraldo P; Vicente V
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S265-7. PubMed ID: 19562501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Using the International Gaucher Disease Registry data: can we devise a virtuous circle for treated patients?
    Elstein D; Zimran A
    Am J Hematol; 2008 Dec; 83(12):887-9. PubMed ID: 18980272
    [No Abstract]   [Full Text] [Related]  

  • 54. Pediatric Gaucher experience in South Marmara region of Turkey.
    Erdemır G; Özkan T; Özgür T; Yazici Z; Özdemır Ö
    Turk J Gastroenterol; 2011 Oct; 22(5):500-4. PubMed ID: 22234757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
    Zimran A; Durán G; Giraldo P; Rosenbaum H; Giona F; Petakov M; Terreros Muñoz E; Solorio-Meza SE; Cooper PA; Varughese S; Alon S; Chertkoff R
    Blood Cells Mol Dis; 2019 Sep; 78():14-21. PubMed ID: 27499018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Competing for the treasure in exceptions.
    Cox TM
    Am J Hematol; 2013 Mar; 88(3):163-5. PubMed ID: 23400870
    [No Abstract]   [Full Text] [Related]  

  • 57. A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight.
    Ucar SK; Coker M; Argin M; Akman S; Kara S; Simsek DG; Darcan S
    Mol Genet Metab; 2009 Jan; 96(1):50-1. PubMed ID: 19006678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Gaucher's disease: a second drug is now available].
    Stirnemann J
    Rev Prat; 2003 Sep; 53(13):1401-2. PubMed ID: 14558259
    [No Abstract]   [Full Text] [Related]  

  • 59. Enzyme replacement therapy in Gaucher's disease.
    Kasturi L; Amin SA
    Indian Pediatr; 2001 Jun; 38(6):686-8. PubMed ID: 11418745
    [No Abstract]   [Full Text] [Related]  

  • 60. Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy.
    Zimran A; Abrahamov A; Elstein D
    Isr Med Assoc J; 2000 Feb; 2(2):80-1. PubMed ID: 10804921
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.